Author:
Lück Hans-Joachim,Du Bois Andreas,Loibl Sibylle,Schrader Iris,Huober Jens,Heilmann Volker,Beckmann Matthias,Stähler Ann,Jackisch Christian,Hubalek Michael,Richter Barbara,Stickeler Elmar,Eidtmann Holger,Thomssen Christoph,Untch Michael,Wollschläger Kerstin,Schuster Tibor,von Minckwitz Gunter
Publisher
Springer Science and Business Media LLC
Reference36 articles.
1. Fossati R, Confalonieri C, Torri V, Ghislandi E, Penna A, Pistotti V, Tinazzi A, Liberati A (1998) Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol 16(10):3439–3460
2. Nabholtz JM, Falkson C, Campos D, Szanto J, Martin M, Chan S, Pienkowski T, Zaluski J, Pinter T, Krzakowski M, Vorobiof D, Leonard R, Kennedy I, Azli N, Murawsky M, Riva A, Pouillart P (2003) TAX 306 Study Group. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol 21(6):968–75. Erratum in: J Clin Oncol 21(10):2048
3. French Epirubicin Study Group (1988) A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. J Clin Oncol 6(4):679–688
4. Hortobagyi GN, Yap HY, Kau SW, Fraschini G, Ewer MS, Chawla SP, Benjamin RS (1989) A comparative study of doxorubicin and epirubicin in patients with metastatic breast cancer. Am J Clin Oncol 12(1):57–62
5. Lück HJ, Thomssen C, Untch M et al (2000) Multicentric Phase III study in first line treatment of advanced metastatic breast cancer (ABC). Epirubicin/Paclitaxel (ET) Vs Epirubicin/Cyclophosphamide (EC). A study of the ago breast cancer Group. Proc ASCO 19:280
Cited by
20 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献